| P50 | author | Hans-Detlev Saeger | Q1576828 |
| | Marius Distler | Q40929009 |
| P2093 | author name string | Stephan Kersting | |
| | Dag Dittert | |
| | Felix Rückert | |
| | Gustavo B Baretton | |
| | Jörg Gastmeier | |
| | Ralf Konopke | |
| P2860 | cites work | Cancer statistics, 2012 | Q27860574 |
| | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| | Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 |
| | Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database | Q33598288 |
| | Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals | Q33610263 |
| | Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial | Q34634440 |
| | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 |
| | Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection | Q34638268 |
| | Reducing hospital morbidity and mortality following esophagectomy | Q35908996 |
| | Resection for esophageal cancer: strategies for optimal management | Q37067954 |
| | Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 |
| | Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. | Q37582787 |
| | Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? | Q38196738 |
| | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. | Q39737918 |
| | Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease | Q43528184 |
| | Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer | Q43620764 |
| | Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model | Q44247929 |
| | Outcomes after esophagectomy: a ten-year prospective cohort | Q44284360 |
| | Outcomes after transhiatal and transthoracic esophagectomy for cancer | Q44448365 |
| | The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma | Q44956855 |
| | Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial | Q45119068 |
| | Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 |
| | Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients | Q47880230 |
| | Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. | Q51699297 |
| | Esophageal Cancer | Q56209683 |
| | Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 |
| | Patterns of Care and Locoregional Treatment Outcomes in Older Esophageal Cancer Patients: The SEER-Medicare Cohort | Q57304491 |
| | Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer | Q80695883 |
| | Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus | Q80859266 |
| | Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model | Q80990549 |
| | National trends in outcomes for esophageal resection | Q81202461 |
| | Endoscopic ultrasound for esophageal and gastroesophageal junction cancer: Impact of increased use of primary neoadjuvant therapy on preoperative locoregional staging accuracy | Q81536291 |
| | Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis | Q82983271 |
| | Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival | Q83705139 |
| | Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer | Q83816934 |
| | Esophageal and esophagogastric junction cancers | Q84909377 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemoradiotherapy | Q5090613 |
| P304 | page(s) | 886-895 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Journal of Gastroenterology and Hepatology | Q15764401 |
| P1476 | title | Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? | |
| P478 | volume | 24 | |